Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $17.69.

ROIV has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Bank of America boosted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 1,983,257 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the sale, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00. Following the completion of the sale, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at $7,193,525.50. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,577,309 shares of company stock worth $42,151,184 over the last three months. 7.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in Roivant Sciences during the 2nd quarter worth about $34,000. Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the 3rd quarter valued at approximately $35,000. Point72 Hong Kong Ltd acquired a new stake in shares of Roivant Sciences in the second quarter valued at about $36,000. US Bancorp DE boosted its holdings in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Finally, Quarry LP purchased a new position in Roivant Sciences in the 2nd quarter valued at $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Up 2.7 %

Shares of ROIV opened at $11.95 on Thursday. The business has a fifty day moving average of $11.78 and a 200 day moving average of $11.31. The company has a market cap of $8.84 billion, a PE ratio of 2.12 and a beta of 1.24. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. Roivant Sciences has a 52-week low of $8.56 and a 52-week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The firm had revenue of $4.48 million for the quarter, compared to the consensus estimate of $34.57 million. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. On average, sell-side analysts expect that Roivant Sciences will post -1.14 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.